Exploring Toxoplasma gondii as a Vector for Targeted Drug Delivery in Rett Syndrome: Potential, Challenges and Future Directions

Rett Syndrome (RTT) is a debilitating neurodevelopmental disorder primarily affecting females, characterized by severe cognitive, motor, and autonomic impairments. The complexity of Rett syndrome and the blood-brain barrier (BBB) significantly limits the effectiveness of conventional treatments. Emerging strategies for targeted drug delivery to the central nervous system (CNS) offer promising avenues for more effective therapies. Among these, the use of Toxoplasma gondii- a neurotropic parasite known for its ability to cross the BBB has garnered attention as a potential vector for targeted drug delivery in RTT. This review explores the potential of Toxoplasma gondii as a novel therapeutic vector for RTT, focusing on its unique biological mechanisms, which enable it to invade and persist within the CNS. The review discusses advancements in genetic engineering that could allow for the safe and controlled delivery of therapeutic agents using this organism. Additionally, the challenges associated with using a live pathogen as a delivery vector, including issues related to safety, immune response, and specificity, are critically examined. Furthermore, the paper highlights the current limitations in preclinical and clinical research, identifies key areas that require further investigation, and proposes future directions for the development of Toxoplasma gondii-based therapies. By assessing both the potential and challenges, this review aims to provide a comprehensive overview of the current state of research and the future possibilities for utilizing Toxoplasma gondii in targeted drug delivery for Rett Syndrome.